IL19 and colitis: Next, we aimed to identify the effect of IL-19 in affecting anxiety-related behaviors in the DSS/CUS-induced comorbidities of colitis and anxiety model; the AAV-IL-19-GFP or AAV-GFP mice were given the CUS/DSS treatment with a shortened period (three days) to explore the role of IL-19 in the time window of progression of DSS/CUS-induced comorbidities of colitis and anxiety (Figure 6A).